Clicky

SENZIME AB AK(6YC)

Description: Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. It offers TetraGraph, a quantitative neuromuscular transmission monitor, which supports neuromuscular blockade management from induction to recovery; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance to measure the tissue's opposition to carrying an alternating electrical current. The company has a strategic connectivity and licensing agreement with Masimo to develop, manufacture, market, and distribute products that can connect to the Masimo Root patient monitoring system and related digital hub for data transmission to hospital electronic patient journals; license agreement with Fukuda Denshi Co. Ltd. to license TetraGraph technology; and license agreement with CoreSpiron (Henan) Co Ltd. to manufacture and sell ExSpiron system. Senzime AB (publ) was incorporated in 1999 and is headquartered in Uppsala, Sweden.


Keywords: Surgery Monitoring Anesthesia Masimo Muscular System Tetra Graph Neuromuscular Blocking Drug

Home Page: www.senzime.com

Ulls vAeg 41
Uppsala, 756 51
Sweden
Phone: 46 18 51 56 40


Officers

Name Title
Mr. Philip Siberg Chief Executive Officer
Mr. Slavoljub Grujicic Chief Financial Officer
Ms. Johanna Tulkki Chief Operating Officer
Mr. Fredrik Norrby Chief Technology Officer
Ms. Rianne Lundqvist Waninge Ph.D. Application Scientist
Ms. Paula Treutiger Head of Communication & Investor Relations
Mr. Anders Selin Executive Vice President of Sales
Mr. Michael Noble Vice President Global Marketing
Mr. Anders Jacobson Chief Innovation Officer
Ms. Catrin Molund Executive Vice President of Business Development

Exchange: F

Country: DE : Germany

Currency: Euro (€)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 2.6866
Price-to-Sales TTM: 1.2051
IPO Date:
Fiscal Year End: December
Full Time Employees: 52
Back to stocks